GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/607,897, a patent which protects delivery of its Sativex® product formulation.
Medical Cannabis News & Information
From 10th April, Sativex will become a Schedule 4 Part I drug and its continued availability for use in healthcare will be enabled under the Misuse of Drugs Regulations 2001 (as amended) (the 2001 Regulations).
The Statutory Instrument, which applies to Great Britain, revokes the Home Office Open General Licence, which currently applies to Sativex, a prescription-only cannabinoid oromucosal mouth spray for use by patients with multiple sclerosis to alleviate symptoms such as neuropathic pain, spasticity or overactive bladder.
CONCORD -- Growing pot outdoors is no longer an option for medical marijuana patients and caregivers.
Despite pleas from medical marijuana users, the City Council on Tuesday voted unanimously to ban the cultivation of medical marijuana outdoors.
Council members said while they understand the medical benefits of marijuana, the risks to public safety were too great.
Randwick, Australia: Adults who inhale cannabis report significantly better health outcomes than do those who smoke tobacco or a combination of both substances, according to exploratory survey data to be published in the journal Addictive Behaviors.
Investigators at the University of New South Wales assessed the relationship between cannabis, tobacco, and combined cannabis-tobacco use and various health outcomes in 350 subjects age 40 and older.
(Reuters) - GW Pharmaceuticals and Almirall may stop selling the cannabis drug Sativex in Germany after health authorities refused to agree a price that the companies view as acceptable.
GW - which developed the under-the-tongue spray as a treatment for spasticity in multiple sclerosis - said on Tuesday the German authorities had determined a price that was significantly lower than in other European countries.